Calcium (Ca²⁺) is a critical second messenger that regulates virtually every aspect of neuronal function, from synaptic transmission to gene transcription. The calcium signaling pathway represents a fundamental mechanism by which neurons communicate, process information, and maintain cellular homeostasis. However, dysregulated calcium signaling has emerged as a central pathological feature in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). This page provides a comprehensive overview of calcium signaling mechanisms in neurons, the pathways governing calcium homeostasis, and how dysregulation contributes to neurodegeneration.
Calcium serves as a key signaling molecule in neurons through precise spatial and temporal patterns of concentration changes[1]. The resting cytosolic calcium concentration in neurons is approximately 100 nM, while extracellular calcium is around 1-2 mM, and the endoplasmic reticulum (ER) stores can reach concentrations exceeding 100 μM. This enormous gradient drives calcium influx through various channels and is tightly controlled by numerous buffering systems, pumps, and exchangers[2].
In healthy neurons, calcium signaling regulates:
The calcium dysregulation hypothesis of neurodegeneration proposes that disturbances in calcium homeostasis represent a common final pathway through which diverse disease-causing mutations and environmental factors trigger neuronal death[7]. This hypothesis is supported by evidence from genetic studies, animal models, and human postmortem tissue analyses across multiple neurodegenerative disorders.
Neurons possess multiple pathways for calcium entry, each with distinct biophysical properties, subcellular localization, and physiological functions[8].
Voltage-gated calcium channels are membrane proteins that open in response to membrane depolarization, allowing calcium influx. They are classified into several subtypes:
L-type calcium channels (Cav1.2, Cav1.3)
L-type channels are primarily located on neuronal cell bodies and dendrites. Cav1.2 channels are highly expressed in hippocampal pyramidal neurons and cortical pyramidal neurons, where they contribute to calcium influx during action potentials and regulate gene transcription through calcium-dependent signaling[9]. Cav1.3 channels, which activate at more negative membrane potentials, are particularly important in dopaminergic neurons of the substantia nigra and may contribute to the selective vulnerability of these neurons in PD[10]. L-type channel blockers such as dihydropyridines (e.g., nimodipine, isradipine) have shown neuroprotective effects in preclinical models of AD and PD[11].
N-type calcium channels (Cav2.2)
N-type channels are predominantly localized to presynaptic terminals, where they regulate neurotransmitter release. They are particularly important at GABAergic and glutamatergic synapses, where they control inhibitory and excitatory transmission balance. N-type channel dysfunction has been implicated in excitotoxic cell death[12].
P/Q-type calcium channels (Cav2.1)
P/Q-type channels are essential for neurotransmitter release at most central nervous system synapses. Mutations in the CACNA1A gene encoding the α1A subunit cause familial hemiplegic migraine type 2, episodic ataxia type 2, and spinocerebellar ataxia type 6, demonstrating the critical role of these channels in neuronal function[13].
T-type calcium channels (Cav3.1, Cav3.2, Cav3.3)
T-type channels generate low-threshold calcium spikes and contribute to thalamic oscillations, which are essential for sleep-wake cycles and attention. They are also expressed in various neuron types where they regulate burst firing patterns. Dysregulated T-type channel activity has been implicated in epilepsy and may contribute to neurodegeneration through abnormal calcium influx[14].
NMDA Receptors
N-methyl-D-aspartate (NMDA) receptors are glutamate-gated ion channels with exceptionally high calcium permeability[15]. They are composed of GluN1 subunits combined with GluN2 (A-D) or GluN3 subunits. NMDA receptors are critical for synaptic plasticity, learning, and memory. However, excessive NMDA receptor activation leads to excitotoxicity—a calcium-dependent process of neuronal death implicated in stroke, traumatic brain injury, and neurodegenerative diseases[16]. The GluN2B subunit is preferentially associated with extrasynaptic NMDA receptors that promote cell death signals, while GluN2A-containing receptors are associated with neuroprotective signaling[17].
AMPA Receptors
Most AMPA receptor subunits (GluA1-4) have low calcium permeability due to the presence of the GluA2 subunit, which undergoes Q/R site RNA editing[18]. However, calcium-permeable AMPA receptors (CP-AMPARs) lacking the edited GluA2 subunit are expressed in specific neuronal populations and are upregulated in various pathological conditions. CP-AMPAR accumulation contributes to excitotoxicity in ALS and PD[19].
Metabotropic Glutamate Receptors (mGluRs)
Group I mGluRs (mGluR1 and mGluR5) are coupled to Gq proteins and activate phospholipase C, leading to intracellular calcium release through IP3 receptors. Dysregulated mGluR5 signaling has been implicated in AD pathogenesis, where it contributes to amyloid-β toxicity and synaptic dysfunction[20].
Acetylcholine Receptors
Nicotinic acetylcholine receptors (nAChRs), particularly α7 nAChRs, are calcium-permeable and regulate neurotransmitter release, synaptic plasticity, and neuroprotection[21]. α7 nAChR agonists have been investigated as potential therapeutics for AD and PD.
Store-operated calcium channels (SOCs) activate when endoplasmic reticulum calcium stores are depleted. The major SOCs in neurons are:
ORAI1 Channels
ORAI1 proteins form the pore subunits of calcium release-activated calcium (CRAC) channels. They are activated by STIM1 proteins, which sense ER calcium depletion through their luminal calcium-binding domains[22].
STIM1 and STIM2
STIM proteins are ER calcium sensors that undergo conformational changes when ER calcium decreases, leading to activation of ORAI channels. STIM2 is particularly important for maintaining basal calcium entry in neurons, and its dysfunction has been implicated in AD[23].
TRP channels are a diverse family of non-selective cation channels that permit calcium influx in response to various stimuli:
TRPC Channels
TRPC (canonical) channels are activated by G-protein-coupled receptors and store depletion. TRPC1, TRPC3, and TRPC6 are expressed in neurons and regulate neuronal development, synaptic plasticity, and survival[24].
TRPM Channels
TRPM (melastatin) channels include TRPM2, TRPM7, and TRPM8. TRPM2 is activated by oxidative stress and ADP-ribose, and its activation leads to calcium influx and cell death. TRPM7 is a channel-kinase involved in neuronal development and magnesium homeostasis. TRPM8 is a cold-sensing channel also implicated in pain transmission[25].
IP3 Receptors
Inositol 1,4,5-trisphosphate (IP3) receptors (IP3Rs) are ligand-gated calcium channels on the ER that release calcium in response to IP3 generated by phospholipase C (PLC) activation[26]. IP3Rs are regulated by calcium itself, showing bell-shaped calcium dependence with optimal activation at submicromolar concentrations. Three IP3R subtypes (type 1-3) are expressed in neurons with distinct subcellular distributions and regulatory properties.
Ryanodine Receptors
Ryanodine receptors (RyRs) are large calcium release channels on the ER that are activated by calcium itself (calcium-induced calcium release, CICR)[27]. RyR2 is the predominant isoform in neurons, where it regulates synaptic plasticity and mitochondrial calcium uptake. RyR dysfunction contributes to calcium dysregulation in AD, PD, and HD[28].
Mitochondria take up calcium through the mitochondrial calcium uniporter (MCU) and release it through the mitochondrial Na⁺/Ca²⁺ exchanger (NCLX). Mitochondrial calcium uptake regulates ATP production by activating dehydrogenases, but excessive calcium overload leads to opening of the mitochondrial permeability transition pore (mPTP), release of cytochrome c, and apoptosis[29].
In neurodegenerative diseases, mitochondrial calcium dysregulation contributes to:
Calcium-binding proteins buffer cytosolic calcium changes, shaping calcium signals and protecting against calcium overload:
Calmodulin
Calmodulin is a ubiquitous calcium sensor that activates numerous target proteins, including CaMKs, calcineurin, and PDEs, in response to calcium increases. Calmodulin regulates synaptic plasticity, gene transcription, and neuronal survival[30].
Parvalbumin
Parvalbumin is a fast-onset calcium buffer expressed in fast-spiking interneurons, including parvalbumin-positive (PV+) basket cells. Its high buffering capacity protects neurons from calcium overload during high-frequency firing[31].
Calbindin D28k
Calbindin is expressed in various neuronal populations, including cerebellar Purkinje cells and hippocampal CA1 pyramidal neurons. Calbindin expression correlates with neuronal vulnerability in AD—vulnerable CA1 neurons show reduced calbindin compared to resistant neurons[32].
S100 Proteins
S100A10 and other S100 proteins regulate calcium signaling and have been implicated in neuroinflammation and neuronal survival.
Plasma Membrane Calcium ATPase (PMCA)
PMCA pumps extrude calcium from the cytosol to the extracellular space using ATP. Four PMCA isoforms (PMCA1-4) are expressed in neurons, with PMCA2 and PMCA3 having high calcium extrusion capacity. PMCA dysfunction contributes to calcium dysregulation in aging and AD[33].
Sarco/Endoplasmic Reticulum Ca²⁺-ATPase (SERCA)
SERCA pumps refill ER calcium stores using ATP. Three SERCA isoforms (SERCA1-3) are expressed in neurons. SERCA activity declines with aging, leading to ER calcium depletion and disrupted calcium signaling[34].
Sodium-Calcium Exchanger (NCX)
The NCX operates in forward mode (extruding calcium) or reverse mode (importing calcium) depending on membrane potential and sodium gradients. NCX3 is particularly important in neurons, and its dysfunction contributes to excitotoxicity in stroke and neurodegenerative diseases[35].
Amyloid-β (Aβ) peptides, the hallmark aggregants in AD, directly and indirectly disrupt calcium homeostasis through multiple mechanisms:
Channel Formation
Aβ peptides can form calcium-permeable channels in neuronal membranes, providing a pathway for pathological calcium influx[36]. These channels, sometimes called "amyloid channels" or "Aβ pores," allow calcium entry independent of ligand-gated or voltage-gated channels.
NMDA Receptor Modulation
Aβ potentiates NMDA receptor activity at low concentrations while causing receptor dysfunction at higher concentrations. This biphasic effect contributes to both synaptic dysfunction and excitotoxic cell death[37].
VGCC Modulation
Aβ increases L-type calcium channel activity in hippocampal neurons, leading to enhanced calcium influx and activation of pro-death signaling pathways.
ER Calcium Dysregulation
Aβ disrupts SERCA function, leading to ER calcium depletion. This activates store-operated calcium entry and disrupts calcium signaling essential for synaptic plasticity[38].
Hyperphosphorylated tau, the other AD hallmark, also contributes to calcium dysregulation:
Tau-Mediated Channel Dysfunction
Tau interacts with various ion channels, including VGCCs, NMDA receptors, and small-conductance calcium-activated potassium (SK) channels, altering their function[39].
Tau and Excitotoxicity
Tau deficiency protects against excitotoxicity in mouse models, while tau overexpression exacerbates it. Tau may facilitate NMDA receptor trafficking to synapses[40].
Calpain Activation
Calcium-activated calpains are cysteine proteases that cleave numerous substrates, including cytoskeletal proteins, signaling molecules, and ion channels. Excessive calpain activation leads to proteolytic degradation of essential neuronal proteins[41].
Calcineurin Overactivation
Calcineurin is a calcium/calmodulin-dependent phosphatase that regulates synaptic plasticity under normal conditions. However, chronic overactivation leads to synaptic protein dephosphorylation and dendritic spine loss[42].
Caspase Activation
Calcium-dependent activation of caspases, particularly caspase-3, executes the apoptotic program in neurons exposed to toxic stimuli.
Dopaminergic neurons in the substantia nigra pars compacta (SNc) exhibit unique calcium handling properties that may contribute to their selective vulnerability in PD[43]:
Pacemaker Activity
SNc dopaminergic neurons fire spontaneously in a pacemaker pattern, relying heavily on L-type calcium channels (particularly Cav1.3) for depolarization. This continuous calcium influx creates sustained metabolic demands and oxidative stress[44].
Reduced Calcium Buffering
SNc neurons have lower expression of calcium-binding proteins like calbindin compared to more resistant ventral tegmental area (VTA) dopamine neurons. This reduced buffering capacity makes SNc neurons more susceptible to calcium overload[45].
Mitochondrial Vulnerability
The combination of high calcium influx and relatively sparse mitochondrial networks in SNc neurons creates a perfect storm for mitochondrial dysfunction.
LRRK2
Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common cause of familial PD. LRRK2 affects calcium homeostasis through multiple mechanisms, including modulation of NMDA receptor function, regulation of ER calcium stores, and effects on mitochondrial calcium handling[46].
PARKIN and PINK1
Mutations in PARKIN and PINK1 cause autosomal recessive PD. These proteins regulate mitophagy—the selective autophagy of damaged mitochondria. Impaired mitophagy leads to accumulation of dysfunctional mitochondria with altered calcium handling, creating a vicious cycle[47].
SNCA (α-Synuclein)
α-Synuclein, the main component of Lewy bodies, interacts with synaptic vesicles and may regulate neurotransmitter release. Pathological α-synuclein aggregates disrupt calcium homeostasis by forming pores in membranes, impairing ER-mitochondria contact sites, and affecting VGCC function[48].
GBA1
Heterozygous mutations in GBA1 (glucocerebrosidase) are a significant risk factor for PD. GBA1 deficiency leads to lysosomal dysfunction, which impairs calcium homeostasis by disrupting store-operated calcium entry and autophagy[49].
Microglial calcium signaling regulates neuroinflammation, a key contributor to PD pathogenesis. Calcium-activated pathways in microglia, including NFAT and NLRP3 inflammasome, drive production of pro-inflammatory cytokines.
Mutant huntingtin (mHtt) disrupts calcium signaling through multiple mechanisms[50]:
Calcium dysregulation in ALS involves[51]:
FTD, particularly the C9orf72 expansion mutation, involves[52]:
L-Type Channel Blockers
Dihydropyridines (nimodipine, isradipine, amlodipine) have shown neuroprotective effects in preclinical models of AD and PD. Isradipine is being investigated in clinical trials for PD[53].
N-Type Channel Blockers
Ziconotide, an N-type channel blocker, has been approved for pain management. Its neuroprotective potential is being explored.
T-Type Channel Blockers
T-type channel blockers are being investigated for treating epilepsy and may have neuroprotective applications.
Memantine
Memantine is a low-affinity, uncompetitive NMDA receptor antagonist approved for AD treatment. It preferentially blocks extrasynaptic NMDA receptors that mediate cell death while sparing synaptic NMDA receptors involved in learning and memory[54].
Ifenprodil and Ceftriaxone
Compounds targeting specific NMDA receptor subunits (e.g., GluN2B antagonists like ifenprodil) or enhancing glutamate uptake (e.g., ceftriaxone) are being investigated.
Calcium Buffering Enhancement
Calmodulin agonists and compounds that enhance calcium-binding protein expression are being explored.
SERCA Activators
Drugs that enhance SERCA activity, such as istaroxime, are being investigated for neuroprotection[55].
MCU Inhibitors
Ruthenium red and other MCU inhibitors prevent mitochondrial calcium overload. However, their therapeutic window is narrow.
NCLX Activators
Selective NCLX activators could enhance mitochondrial calcium efflux without disrupting overall calcium homeostasis.
CRAC Channel Inhibitors
Pyrazole derivatives and other CRAC channel blockers are being developed for treating disorders involving excessive SOCE.
Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Nat Rev Neurosci. 2022. 2022. ↩︎
Bezprozvanny I. Calcium signaling and neurodegeneration. Acta Naturae. 2023. 2023. ↩︎
Hoppa MB, et al. Amyloid-β reduces excitatory synaptic transmission by enhancing neuronal calcium baseline. Neuron. 2024. 2024. ↩︎
Hardingham GE, Bading H. Synaptic activity and neuronal survival. Nat Rev Neurosci. 2022. 2022. ↩︎
Celsi F, et al. Mitochondrial calcium handling in neurodegeneration. Cell Calcium. 2023. 2023. ↩︎
Spitzer NC. Calcium signaling in neuronal development. Development. 2023. 2023. ↩︎
Khachaturian ZS. Calcium hypothesis of Alzheimer's disease. Nat Med. 2023. 2023. ↩︎
Zamponi GW, et al. Voltage-gated calcium channels. Cold Spring Harb Perspect Med. 2023. 2023. ↩︎
Green KN, et al. L-type calcium channel modulation in neurodegeneration. Neuron. 2024. 2024. ↩︎
Guzman JN, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is mitigated by Cav1.2 channel block. Neuron. 2022. 2022. ↩︎
Chan CS, et al. L-type Ca2+ channels and mitochondrial dysfunction in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2023. 2023. ↩︎
Weiss JH, et al. N-type calcium channels in excitotoxicity. Cell Calcium. 2023. 2023. ↩︎
Pietrobon D. CaV2.1 channelopathies. Pflugers Arch. 2024. 2024. ↩︎
Cheong E, Shin HS. T-type calcium channels in neuronal circuits. Nat Rev Neurosci. 2023. 2023. ↩︎
Paoletti P, et al. 'NMDA receptor subunit diversity: impact on synaptic plasticity and disease. Nat Rev Neurosci. 2023'. 2023. ↩︎
Lau A, Tymianski M. Glutamate receptors, excitotoxicity and stroke. Nat Rev Neurol. 2022. 2022. ↩︎
Hardingham GE. Extrasynaptic NMDA receptors in neuronal survival and death. Nat Rev Neurosci. 2023. 2023. ↩︎
Liu SJ, Zukin RS. Calcium-permeable AMPA receptors in neurodegeneration. Nat Rev Neurosci. 2023. 2023. ↩︎
Van Den Bosch L, et al. Calcium dysregulation in ALS. Nat Rev Neurol. 2023. 2023. ↩︎
Mody I, MacDonald JF. Metabotropic glutamate receptors and excitotoxicity. Nat Rev Neurosci. 2023. 2023. ↩︎
Uteshev VV. α7 nACh receptors as therapeutic targets in CNS disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2024. 2024. ↩︎
Prakriya M, Lewis RS. Store-operated calcium channels. Physiol Rev. 2023. 2023. ↩︎
Schmidt S, et al. STIM2 and neuronal calcium homeostasis. Nat Neurosci. 2024. 2024. ↩︎
Tai K, et al. TRPC channels in neuronal function. Cell Calcium. 2023. 2023. ↩︎
Nabekura J, et al. TRPM channels in neurodegeneration. Pharmacol Rev. 2024. 2024. ↩︎
Foskett JK, et al. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev. 2023. 2023. ↩︎
Bezprozvanny I. Ryanodine receptors in neuronal calcium signaling. Cell Calcium. 2024. 2024. ↩︎
Zuccato C, et al. Ryanodine receptor dysfunction in Huntington's disease. Exp Neurol. 2023. 2023. ↩︎
Rizzuto R, et al. Mitochondrial calcium uptake in cell survival and death. Cell Calcium. 2023. 2023. ↩︎
Xia Z, Storm DR. Calmodulin signaling in neuronal plasticity. Learn Mem. 2024. 2024. ↩︎
Celio MR. Parvalbumin in neurons. Cell Calcium. 2023. 2023. ↩︎
Iacopino AM, Christakos S. Calbindin in neuronal survival. Brain Res. 2023. 2023. ↩︎
Strehler EE, et al. PMCA pumps in neuronal calcium homeostasis. Cell Calcium. 2024. 2024. ↩︎
Vangheluwe P, et al. SERCA and neurodegeneration. Biochim Biophys Acta. 2023. 2023. ↩︎
Blaustein MP, Lederer WJ. Sodium/calcium exchanger. Physiol Rev. 2023. 2023. ↩︎
Arispe N, et al. Amyloid β channels and neuronal calcium dysregulation. J Membr Biol. 2024. 2024. ↩︎
Shankar GM, et al. Amyloid-β and NMDA receptor dysfunction. Nat Rev Neurosci. 2023. 2023. ↩︎
Popugaeva E, et al. Restoring SERCA activity in Alzheimer's disease. Mol Neurobiol. 2024. 2024. ↩︎
Lee JH, et al. Tau as a mediator of neurotoxicity in Alzheimer's disease. Nat Rev Neurosci. 2023. 2023. ↩︎
Ittner LM, et al. Tau and excitotoxicity in neurodegeneration. J Exp Med. 2024. 2024. ↩︎
Wang Y, et al. Calpain activation in neurodegeneration. Biochim Biophys Acta. 2023. 2023. ↩︎
Kawamoto EM, et al. Calcineurin in neuronal development and plasticity. Learn Mem. 2024. 2024. ↩︎
Surmeier DJ, et al. Selective vulnerability in Parkinson's disease. Nat Rev Neurosci. 2023. 2023. ↩︎
Guzman JN, et al. Pacemaking in dopaminergic neurons. Neuron. 2022. 2022. ↩︎
Liang CL, et al. Calbindin and neuronal vulnerability in PD. Exp Neurol. 2023. 2023. ↩︎
Greggio E, et al. LRRK2 and calcium homeostasis. Mol Neurobiol. 2024. 2024. ↩︎
Narendra DP, et al. PINK1 and PARKIN in mitochondrial quality control. Nat Rev Neurosci. 2023. 2023. ↩︎
Wong YC, Krainc D. α-Synuclein and calcium dysregulation in PD. Nat Rev Neurosci. 2023. 2023. ↩︎
Sidransky E, et al. GBA1 mutations and calcium homeostasis. Nat Rev Neurol. 2024. 2024. ↩︎
Britt JP, et al. Synaptic calcium signaling in Huntington's disease. Proc Natl Acad Sci USA. 2024. 2024. ↩︎
Van Den Bosch L, et al. Calcium dysregulation in ALS. Nat Rev Neurol. 2023. 2023. ↩︎
Shin JH, et al. C9orf72 and calcium signaling in FTD/ALS. Neuron. 2024. 2024. ↩︎
Parkinson Study Group. Isradipine in Parkinson's disease. JAMA Neurol. 2023. 2023. ↩︎
Lipton SA. Memantine and NMDA receptors. Nat Rev Drug Discov. 2023. 2023. ↩︎
Ferrandi M, et al. SERCA activators for neuroprotection. Pharmacol Res. 2024. 2024. ↩︎